Alloxan targets pancreatic β-cells through multiple mechanisms. It generates reactive oxygen species (ROS) including superoxide radicals that cause selective β-cell toxicity. Alloxan inhibits glucokinase, impairing glucose sensing in β-cells. It also functions as a proteasome inhibitor. The compound is a substrate for the GLUT2 glucose transporter, which facilitates its selective uptake into β-cells, where it exerts its toxic effects through redox cycling and free radical generation.

In vitro, alloxan exhibits selective toxicity toward pancreatic β-cells through ROS generation and glucokinase inhibition. It inhibits sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 μM. Alloxan shows concentration-dependent cytotoxicity in insulin-producing cell lines such as MIN6 and RINm5F, with typical IC50 values in the low millimolar range depending on exposure time and cell type. It also inhibits proteasome activity in cell-free systems.

In vivo, alloxan is used as a diabetogenic agent to induce diabetes in experimental animals. It selectively induces pancreatic β-cell death through ROS generation. Dosing protocols vary by species: hamsters receive 300 mg/kg intramuscularly, while rats and mice receive 170-400 mg/kg subcutaneously. Alloxan causes diabetes mellitus through β-cell destruction, with effects on fertility, retina, blood, brain, and liver at toxic doses. Its extreme aqueous instability (t½ ~1.5 min) can cause irreproducible diabetes induction.

Cell-free assays for alloxan typically involve measurement of ROS generation using fluorescent probes such as dichlorofluorescein diacetate (DCFH-DA). Standard protocols include incubation of alloxan at concentrations of 0.1-10 mM in phosphate-buffered saline (pH 7.4) at 37°C for 15-60 minutes, with fluorescence measurement at 485/530 nm. Glucokinase inhibition assays involve incubation of recombinant glucokinase with glucose (5-50 mM), ATP (1-10 mM), and alloxan (0.1-10 mM), followed by measurement of NADH production at 340 nm.

In vitro cell-based assays for alloxan typically involve treatment of insulin-producing cell lines (e.g., MIN6, RINm5F, INS-1) or isolated pancreatic islets. Cells are exposed to alloxan at concentrations of 0.1-20 mM for 1-24 hours at 37°C in glucose-containing medium. Cell viability is assessed by MTT, trypan blue exclusion, or LDH release. Insulin secretion is measured by ELISA or radioimmunoassay. ROS generation is detected by DCFH-DA fluorescence. Apoptosis is evaluated by Annexin V staining, caspase-3 activity, and TUNEL assay.

In vivo animal protocols for alloxan-induced diabetes typically involve a single intravenous or intraperitoneal injection in rodents. Rats receive 40-65 mg/kg intravenously or 150-200 mg/kg intraperitoneally; mice receive 50-100 mg/kg intravenously or 150-200 mg/kg intraperitoneally. Fasted animals (12-24 hours) are used to enhance β-cell susceptibility. Blood glucose is measured at baseline and at 24, 48, 72 hours, and weekly post-injection. Diabetes is defined as fasting blood glucose >250 mg/dL or non-fasting >300 mg/dL. Streptozotocin is often used as an alternative diabetogenic agent with more consistent effects.

Absorption, Distribution and Excretion
This study investigated the uptake of [2-(14)C]aloxane in the pancreas of normal rats and streptozotocin-induced diabetic (STZ) rats using in vitro and in vivo techniques. Whether pancreatic tissue blocks were incubated with [2-(14)C]aloxane for 10 to 60 minutes, or 60 minutes to 24 hours after intravenous injection of [2-(14)C]aloxane into normal rats and insulin-treated STZ rats, the radioactivity content (dpm/mg wet weight) in the pancreas of STZ rats was only about two-thirds of the reference value in normal rats. These findings suggest that although pancreatic β-cells constitute only about one percent of the total mass of the pancreas, they play a significant role in the overall uptake of [2-(14)C]aloxane by the pancreas. Therefore, from the perspective of non-invasive imaging and quantitative analysis, a suitable radiolabeled molecule that can be selectively taken up by islet cells (rather than acinar cells) should be available to preferentially label the endocrine portion of the pancreas.

---

Metabolism/Metabolites
Aloxan is reduced to diurate. Diurate is then re-oxidized back to aloxan, forming a redox cycle that generates superoxide radicals. The reaction of aloxan with diurate produces the intermediate aloxan radical and an unknown compound with maximum absorption at 305 nm. The latter occurs during the reduction of alloxaden by glutathione (GSH). …One of the targets of reactive oxygen species is pancreatic DNA.
Alloxaden…in the absence of a reducing agent, breaks down into alloxa acid. In the presence of glutathione, it is reduced to diurate via the alloxaden radical, which is then auto-oxidized back to alloxaden. This redox cycle generates reactive oxygen species that damage β cells in the pancreas. …
This in vitro study compared the frequency of the redox cycle between alloxaden and diurate at different initial glutathione and alloxaden ratios. Alloxaden oxidizes GSH to GSSG. At an initial GSH concentration of 2.0 mmol/L, the oxidation rate of GSH depends on the initial concentration of alloxazone added. A higher alloxazone concentration relative to the initial GSH concentration results in a faster GSH oxidation rate, greater oxygen consumption, and therefore, more reactive oxygen species (ROS) generation. The highest GSH oxidation rate (i.e., GSSG generation rate) is observed when the GSH to alloxazone ratio is 2.0 mmol/L, 0.2 mmol/L, and 0.04 mmol/L, respectively. Since 0.04 mmol/L alloxazone can completely oxidize 2.0 mmol/L GSH, it can be inferred that at least 25 cycles occur between alloxazone and diuric acid within 3 hours. In each redox cycle, two GSH molecules are oxidized to one GSSG molecule, while one oxygen molecule is reduced to one hydrogen peroxide molecule. Therefore, in total, one alloxazone molecule oxidizes at least 50 GSH molecules and generates approximately 25 hydrogen peroxide molecules.

Interactions
This study tested the hypoglycemic activity of the methanol leaf extract of Bauhinia cheilandra (BC) on glucose-loaded and alloxan-induced diabetic rats. In both tests, methanol extracts at doses of 300, 600, and 900 mg/kg all showed statistically significant hypoglycemic activity. This study analyzed the antidiabetic properties of the ethanol extract of Psidium guajava stem bark. Guava is a native medicinal plant used in traditional Indian medicine to treat diabetes. This study evaluated the hypoglycemic activity of this plant on blood glucose levels in normal rats, rats under normal glucose load (oral glucose tolerance test, OGTT), and rats with alloxan-induced hyperglycemia. The results showed that the ethanol stem bark extract exhibited statistically significant hypoglycemic activity in the alloxan-induced hyperglycemic rat model, but no significant hypoglycemic effect was observed in normal rats and rats under normal glucose load (oral glucose tolerance test, OGTT).
Administering nicotinamide 10 minutes before alloxan injection protected NMRI mice from alloxan-induced hyperglycemia, but administration 10 minutes after injection had no effect. In vivo nicotinamide pretreatment induced hyperglycemia upon alloxan injection, which may explain the protective effect of nicotinamide against alloxan-induced diabetes.
This study aimed to investigate the effects of onion (Allium cepa Linn) and garlic (Allium sativum Linn) juices on biochemical parameters, enzyme activity, and lipid peroxidation in alloxan-induced diabetic rats. Alloxan was administered as a single dose (120 mg/kg body weight) to induce diabetes. Alloxan-induced diabetic rats were orally administered onion or garlic juice at a dose of 1 mL/100 g body weight (equivalent to 0.4 g/100 g body weight) daily for four weeks. Compared with the control group, plasma glucose, urea, creatinine, and bilirubin levels in alloxan-induced diabetic rats were significantly increased (p<0.05). In alloxan-induced diabetic rats, the activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and acid phosphatase (AcP) were significantly increased in plasma and testes (p<0.05), while the activities of these enzymes were decreased in the liver. LDH activity in brain tissue was also significantly increased (p<0.05). In alloxan-induced diabetic rats, the concentrations of thiobarbituric acid reactants and the activity of glutathione S-transferase were all increased in plasma, liver, testes, brain, and kidneys. Repeated treatment with garlic or onion juice in diabetic rats restored these indicators to normal levels…
For more complete data on alloxan interactions (11 in total), please visit the HSDB records page.

[1]. Diabetogenic agent alloxan is a proteasome inhibitor. Biochem Biophys Res Commun. 2017;488(2):400-406.

Therapeutic Uses
/Exptl Ther/ Two patients with islet cell hyperplasia…experienced recurrent hypoglycemia after subtotal pancreatectomy. They were successfully treated with aloxan (methoxazine).

C4H2N2O4

142.001

50-71-5

5781

Orthorhombic crystals from anhydrous acetone or glacial acetic acid or by sublimation in vacuo. Turns pink at 230 °C ... Hot aqueous solutions are yellow and become colorless on cooling

1.7±0.1 g/cm3

409.5ºC at 760 mmHg

~245 °C (dec.)

201.4ºC

1.519

Originated from plants: Meliaceae Azadirachta indica A. Juss.

-1.84

2

4

0

10

222

0

O=C1C(NC(NC1=O)=O)=O

HIMXGTXNXJYFGB-UHFFFAOYSA-N

InChI=1S/C4H2N2O4/c7-1-2(8)5-4(10)6-3(1)9/h(H2,5,6,8,9,10)

2,4,5,6(1H,3H)-Pyrimidinetetrone

Alloxan NSC-7169 NSC7169NSC 7169

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)